<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214721</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-RENAL-REG-062</org_study_id>
    <nct_id>NCT00214721</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis</brief_title>
  <official_title>A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <brief_summary>
    <textblock>
      Objective: The purpose of this study is to demonstrate:&#xD;
&#xD;
      -the non-inferiority of an experimental peritoneal dialysis solution compared to a current&#xD;
      solution for the management of end stage renal disease (ESRD) in peritoneal dialysis&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date>July 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>120</enrollment>
  <condition>End Stage Renal Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Peritoneal Dialysis Solution</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have given written informed consent after the nature of the study has&#xD;
             been explained.&#xD;
&#xD;
          -  Patients who are at least 18 years of age.&#xD;
&#xD;
          -  Patients who have been treated with CAPD using specific solutions for at least 60 days&#xD;
             before the baseline visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received antibiotics for the treatment of an episode of peritonitis&#xD;
             within 30 days before the screening visit. - Patients who have had acute or chronic&#xD;
             exit-site or tunnel infection in the past 14 days, counted from the last day of&#xD;
             infection to the screening visit.&#xD;
&#xD;
          -  Patients who have other serious diseases, such as active, or if previously treated,&#xD;
             residual malignancy or systemic infection.&#xD;
&#xD;
          -  Patients who have had a major illness or injury requiring hospitalisation within 30&#xD;
             days before the baseline visit.&#xD;
&#xD;
          -  Patients who have severe malnutrition (serum albumin &lt; 25 g/l by bromocresol green&#xD;
             method).&#xD;
&#xD;
          -  Patients who are participating in another study that requires Ethics Committee&#xD;
             approval. Non-interventional studies are permitted.&#xD;
&#xD;
          -  Patients who have received an investigational product within 30 days preceding the&#xD;
             screening visit.&#xD;
&#xD;
          -  Patients who are pregnant or lactating. (NB: Female patients of childbearing potential&#xD;
             must have a negative urine or serum pregnancy test at the time of the screening and&#xD;
             will be required to use a medically acceptable means of contraception during their&#xD;
             participation in this study).&#xD;
&#xD;
          -  Patients who have a significant psychiatric disorder or mental disability that could&#xD;
             interfere with his/her ability to provide informed consent and/or comply with protocol&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlene Stubbs</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>November 28, 2007</last_update_submitted>
  <last_update_submitted_qc>November 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

